ClinicalTrials.gg
RecruitingNCT07613424GenometUpdated Oct 26, 2026

A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)

An interventional study of NGS testing and MET IHC testing in Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Recruiting at 51 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by AstraZeneca · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 26, 2026Site recruiting status changed49 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca — 26 open to participants now, 79 under way, 28 of them phase 3. Carcinoma, Non-Small-Cell Lung · AstraZeneca.

Planned enrollment
10th of 138
1,000 · median 153
Started
2026
with 8 others
No phase
2 of 210
1 open now
Primary completion
2027-03
later than 45 of 78 live
Registered
207th of 210
by date

Among the 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 10th largest by planned enrollment of the 138 interventional ones that give a count, is one of 9 that started in 2026, is one of 2 with no phase, reaches primary completion later than 45 of the 78 other live ones, and was the 207th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

26 of the 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 26 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, or all of them as a file.
02

Study summary

Multicenter prospective assessment of MET concordance and tumor gene profiling in treatment-naïve NSCLC

Read the detailed description

The primary objective of the study is to evaluate the agreement among four different test methods with a reference assay for MET OverExp. Analyses for primary endpoints will be conducted in assays concordance analysis set (ACS).

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • MET Concordance
  • Gene Profiling
  • NSCLS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

Age

  1. Participant must be ≥ 18 at the time of signing the . Type of Participant and Disease Characteristics
  2. Participants who are in accordance with the Eighth Edition of TNM Staging of Lung Cancer by the International Association for the Study of Lung Cancer and American Joint Committee on Cancer, or cytologically confirmed unresectable locally advanced (Stage ⅢB/ⅢC), or recurrent (Stage IV) NSCLC.
  3. Willing to provide adequate tissue sample:

1Biopsy tissue must be collected after confirmation of unresectable locally advanced (Stage IIIB/IIIC), metastatic, or recurrent (Stage IV) NSCLC diagnosis, and before initiation of any antitumor therapy. The specimens require at least 16 FFPE slides.

or 2Surgical specimens only for patients with recurrent disease who either received no therapy, or received only adjuvant chemotherapy and recurrence occurred >6 months after completing chemotherapy. The surgical specimens require at least 13 FFPE slides (surgical specimens obtained within 2 years before ICF signing).

Informed Consent 4.Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

5.Provision of signed and dated, written informed consent form prior to any mandatory study-specific procedures, sampling, and analyses.

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  1. Currently having other malignant tumors, or having other infiltrating malignant tumors in the past 5 years. Stage I malignant tumor after radical treatment for at least 3 years, except those considered by investigators to have a small possibility of recurrence. Participants with radically treated carcinoma in situ (non-infiltrating), papillary thyroid carcinoma and skin cancer other than malignant melanoma can be enrolled.
  2. Prior radiotherapy or systemic therapy for unresectable locally advanced (Stage IIIB/IIIC) or /recurrent (Stage IV) NSCLC, except patients initiating therapy for this specific disease stage within 1 month before ICF signing.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Other
    cohort 1

    Participants will be assigned to study cohorts based on the EGFR mutation status determined by central NGS testing. Only participants with EGFR mutations (EGFR 19del+/L858R+) will be included in Cohort 1.

    Diagnostic Test: NGS testing · Diagnostic Test: MET IHC testing

  • Other
    cohort 2

    Participants will be assigned to study cohorts based on the EGFR mutation status determined by central NGS testing.Those with no actionable genomic alterations (non-AGA), defined as EGFR 19del-/L858R-/20ins-/PACC-, ALK-, ROS1-, BRAF V600-, NTRK-, KRAS G12C-, MET amp-, MET exon14-, and RET-, will be assigned to Cohort 2.

    Diagnostic Test: NGS testing · Diagnostic Test: PD-L1 and Her2 testing

  • Other
    cohort 3

    Participants will be assigned to study cohorts based on the EGFR mutation status determined by central NGS testing.Those with other actionable genomic alterations (AGA, excluding EGFR 19del+/L858R+), defined as EGFR 20ins+, EGFR PACC+, ALK+, ROS1+, BRAF V600+, NTRK+, KRAS G12C+, MET amp+, MET exon14+, or RET+, will be assigned to Cohort 3.

    Diagnostic Test: NGS testing

Interventions

  • Diagnostic testNGS testing

    NGS testing first for all participants and then cohort assignment for each participant can be derived based on NGS results.

  • Diagnostic testMET IHC testing

    the participants of cohort 1 need to do MET IHC testing.

  • Diagnostic testPD-L1 and Her2 testing

    the participants of cohort 1 need to do PD-L1 and Her2 testing.

06

What researchers measure

Primary outcomes

  1. OPA/PPA/NPA

    The primary objective is to evaluate the agreement among four different test methods with a reference assy for MET OverExpression. Key agreement metrics includes Overall Percent Agreement (OPA),Positive percent agreement (PPA),Negative percent agreement (NPA).

    Time frame: 90 days after LPI

Secondary outcomes

  1. OPA/PPA/NPA

    The testing concordance between central lab and local labs using Amoy D1C2 assay will be evaluated by the metrisc including OPA/PPA/NPA.

    Time frame: 90 days after LPI

  2. Fleiss's Kappa

    Fleiss's Kappa will be calculated to assess the inter-rater agreement of MET IHC interpretation made by 20 pathologists.

    Time frame: 90 days after LPI

  3. Treatment pattern

    The number and percentage of participants in cohort 1 and cohort 2 using different treatment patterns will be summarized.

    Time frame: 90 days after LPI

  4. Biomarker profiling

    Gene profiling by tissue NGS

    Time frame: 90 days after LPI

  5. Biomarker profiling

    •Proportion of MET OverExp in cohort 1

    Time frame: 90 days after LPI

  6. Biomarker profiling

    •Proportion of HER2 OverExp in cohort 2

    Time frame: 90 days after LPI

  7. Biomarker profiling

    •Proportion of HER2m, HER2 amp, MET exon14 in overall population

    Time frame: 90 days after LPI

  8. Biomarker profiling

    •Proportion of HER2 OverExp \& PD-L1+ in cohort 2

    Time frame: 90 days after LPI

07

Study locations

50 of 51 sites recruiting
  • Research Site
    Anyang, 455000, China
    Recruiting
  • Research Site
    Baoding, 071000, China
    Recruiting
  • Research Site
    Beijing, 100210, China
    Recruiting
  • Research Site
    Cangzhou, 061001, China
    Recruiting
  • Research Site
    Changzhi, 046000, China
    Recruiting
  • Research Site
    Chengdu, 610031, China
    Recruiting
  • Research Site
    Chengdu, 610041, China
    Recruiting
  • Research Site
    Fuzhou, 350005, China
    Recruiting
  • Research Site
    Guangzhou, 510000, China
    Recruiting
  • Research Site
    Guangzhou, 510120, China
    Recruiting
  • Research Site
    Guangzhou, 510515, China
    Recruiting
  • Research Site
    Handan, 130403, China
    Recruiting
  • Research Site
    Hefei, 133500, China
    Recruiting
  • Research Site
    Huzhou, 313003, China
    Recruiting
  • Research Site
    Jinan, 250011, China
    Recruiting
  • Research Site
    Jinan, 250021, China
    Recruiting
  • Research Site
    Jining, 272011, China
    Recruiting
  • Research Site
    Linhai, 317000, China
    Recruiting
  • Research Site
    Linyi, CN-276003, China
    Recruiting
  • Research Site
    Lishui, 323000, China
    Recruiting
  • Research Site
    Liuzhou, 545006, China
    Recruiting
  • Research Site
    Nanchang, 330000, China
    Recruiting
  • Research Site
    Nanjing, 210000, China
    Recruiting
  • Research Site
    Nanning, 530021, China
    Recruiting
  • Research Site
    Nantong, 226001, China
    Recruiting
  • Research Site
    Qiqihar, 161005, China
    Recruiting
  • Research Site
    Shanghai, 200080, China
    Recruiting
  • Research Site
    Shanghai, 200433, China
    Recruiting
  • Research Site
    Shaoxing, 312000, China
    Recruiting
  • Research Site
    Shenyang, 110042, China
    Recruiting
  • Research Site
    Shenzhen, 518039, China
    Recruiting
  • Research Site
    Shijiazhuang, 50051, China
    Recruiting
  • Research Site
    Shiyan, 442000, China
    Recruiting
  • Research Site
    Suining, 629000, China
    Recruiting
  • Research Site
    Taiyuan, 030000, China
    Recruiting
  • Research Site
    Taiyuan, 030032, China
    Recruiting
  • Research Site
    Tangshan, 63000, China
    Not yet recruiting
  • Research Site
    Tianjin, 300192, China
    Recruiting
  • Research Site
    Tianjin, 300222, China
    Recruiting
  • Research Site
    Weifang, 261000, China
    Recruiting
  • Research Site
    Wenzhou, 325000, China
    Recruiting
  • Research Site
    Wuhan, 430000, China
    Recruiting
  • Research Site
    Wuhan, 430030, China
    Recruiting
  • Research Site
    Wuhu, 241000, China
    Recruiting
  • Research Site
    Wuhu, 241004, China
    Recruiting
  • Research Site
    Xi'an, 710114, China
    Recruiting
  • Research Site
    Xiamen, 361004, China
    Recruiting
  • Research Site
    Xiangyang, 441000, China
    Recruiting
  • Research Site
    Yangzhou, 225001, China
    Recruiting
  • Research Site
    Zhoushan, 316000, China
    Recruiting
  • Research Site
    Zunyi, 563100, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Mar 2027, 9 months after the start.

Of 361 interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 97. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 29, 2026
StartActual
Jun 2, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
49 sites added. Research Site is now Recruiting
Show 49 added (49 China)
  • Research Site · Anyang, China
  • Research Site · Baoding, China
  • Research Site · Cangzhou, China
  • Research Site · Changzhi, China
  • Research Site · Chengdu, China
  • Research Site · Chengdu, China
  • Research Site · Fuzhou, China
  • Research Site · Guangzhou, China
  • Research Site · Guangzhou, China
  • Research Site · Guangzhou, China
  • Research Site · Handan, China
  • Research Site · Hefei, China
  • Research Site · Huzhou, China
  • Research Site · Jinan, China
  • Research Site · Jinan, China
  • Research Site · Jining, China
  • Research Site · Linhai, China
  • Research Site · Linyi, China
  • Research Site · Lishui, China
  • Research Site · Liuzhou, China
  • Research Site · Nanchang, China
  • Research Site · Nanjing, China
  • Research Site · Nanning, China
  • Research Site · Nantong, China
  • Research Site · Qiqihar, China
  • Research Site · Shanghai, China
  • Research Site · Shaoxing, China
  • Research Site · Shenyang, China
  • Research Site · Shenzhen, China
  • Research Site · Shijiazhuang, China
  • …and 19 more on the registry record
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    49 sites added. Research Site is now Recruiting
    Show 49 added (49 China)
    • Research Site · Anyang, China
    • Research Site · Baoding, China
    • Research Site · Cangzhou, China
    • Research Site · Changzhi, China
    • Research Site · Chengdu, China
    • Research Site · Chengdu, China
    • Research Site · Fuzhou, China
    • Research Site · Guangzhou, China
    • Research Site · Guangzhou, China
    • Research Site · Guangzhou, China
    • Research Site · Handan, China
    • Research Site · Hefei, China
    • Research Site · Huzhou, China
    • Research Site · Jinan, China
    • Research Site · Jinan, China
    • Research Site · Jining, China
    • Research Site · Linhai, China
    • Research Site · Linyi, China
    • Research Site · Lishui, China
    • Research Site · Liuzhou, China
    • Research Site · Nanchang, China
    • Research Site · Nanjing, China
    • Research Site · Nanning, China
    • Research Site · Nantong, China
    • Research Site · Qiqihar, China
    • Research Site · Shanghai, China
    • Research Site · Shaoxing, China
    • Research Site · Shenyang, China
    • Research Site · Shenzhen, China
    • Research Site · Shijiazhuang, China
    • …and 19 more on the registry record
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07613424
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Jun 2, 2026
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion